Linezolida Krka (Linezolid)

Linezolid is employed to treat infections caused by Gram‑positive bacteria, targeting resistant organisms and respiratory or skin conditions.

• MRSA and VRE infections: effective bacterial eradication in serious Gram‑positive infections.
• Community‑acquired and nosocomial pneumonia: improves clinical outcomes in lung infections.
• Skin and soft‑tissue infections: resolves complicated cellulitis and wound infections.
• Ventilator‑associated pneumonia: provides coverage for resistant pathogens in intubated patients.
• Hospital‑acquired pneumonia: used when other agents are ineffective against Gram‑positive organisms.
• Complicated skin and soft‑tissue infections: treats deep tissue infections caused by resistant bacteria.

• Linezolid exerts its antibacterial activity by binding to the 50S ribosomal subunit of susceptible bacteria. This interaction prevents the formation of the initiation complex required for protein synthesis, resulting in a bacteriostatic effect that inhibits bacterial growth and replication. The drug’s unique binding site distinguishes it from other protein synthesis inhibitors. Because it does not target the peptidyl transferase center, cross‑resistance with other classes is minimal, allowing use against strains resistant to macrolides, lincosamides, and streptogramins.

Linezolid may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild gastrointestinal upset, usually transient.
• Diarrhea: loose stools that are often self‑limiting.
• Headache: transient cranial discomfort, may respond to analgesics.
• Metallic taste: altered taste perception, generally resolves after therapy.

Serious or Rare Side Effects

• Thrombocytopenia: significant drop in platelet count, may increase bleeding risk.
• Peripheral neuropathy: nerve damage causing numbness or tingling, can be irreversible.
• Serotonin syndrome: potentially life‑threatening reaction when combined with serotonergic agents, requires urgent care.
• Optic neuropathy: visual disturbances that may be irreversible, necessitates immediate evaluation.

When prescribing linezolid, clinicians should consider several precautionary measures to ensure patient safety.

• Renal function: assess baseline kidney function and monitor periodically, especially in patients with pre‑existing renal impairment.
• Hematologic monitoring: obtain a baseline complete blood count and repeat during therapy to detect thrombocytopenia, anemia, or leukopenia.
• Serotonergic agents: avoid concomitant use with SSRIs, MAOIs, or other serotonergic drugs because of the risk of serotonin syndrome.
• Duration of therapy: limit treatment to the prescribed length, typically not exceeding 28 days, to minimize resistance and adverse effects.
• Store at ambient temperature: keep in the original packaging, protect from moisture and heat, and store below 25 °C.

Linezolid can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• SSRIs, SNRIs, and other serotonergic antidepressants: risk of serotonin syndrome.
• Monoamine oxidase inhibitors (MAOIs): heightened serotonin toxicity.
• Riluzole: increased potential for serotonin syndrome.

Moderate Interactions (Monitor Closely)

• Warfarin: linezolid may potentiate anticoagulant effect, increasing INR.
• Phenytoin: may reduce linezolid plasma concentrations, decreasing efficacy.
• Rifampicin: enzyme induction can lower linezolid exposure, possibly leading to therapeutic failure.